Search clinical trials for: RET fusion

Total 36071 results

Rigshospitalet, Denmark

Completed

Image Fusion PET, CT and 3D-ultrasound Examinations

Anal Cancer

Denmark
Instituto Nacional de Ciencias Medicas y Nutricion...
University of Pennsylvania; University of Witwatersrand, South Africa; Case Western... and other collaborators

Unknown

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients (CADIRIS)

HIV Infections | HIV | Immune Reconstitution Inflammatory Syndrome

Mexico, United States, South Africa
ViiV Healthcare
Pfizer

Completed

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

HIV-1
Rockefeller University
Pfizer; Aaron Diamond AIDS Research Center

Completed

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

HIV Infections

United States
Kristine Patterson, MD
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Sex, Aging and Antiretroviral Pharmacokinetics

HIV Infections

United States
ViiV Healthcare
Pfizer

Completed

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Healthy

Belgium
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
Pedro Cahn
Abbott

Completed

Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects. (GARDEL)

HIV Infection

Argentina
Canadian Immunodeficiency Research Collaborative
Hoffmann-La Roche

Completed

Fuzeon Viral Decay Pilot Study

HIV-1

Canada
GlaxoSmithKline

Completed

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

Infection, Human Immunodeficiency Virus I
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)

HIV Infections

Netherlands, United States, Italy, Spain, United Kingdom, France, Germany, Australia, Switzerland, Belgium, Canada, Poland, Sweden
University of North Carolina, Chapel Hill

Terminated

Study of Valproic Acid to Treat HIV Infected Adults

HIV Infections

United States
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 1)

HIV Infections

United States, Canada
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI); St Vincent's Hospital, Sydney

Completed

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Cardiovascular Disease | HIV-Associated Lipodystrophy Syndrome

Australia
St Stephens Aids Trust

Completed

PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen (SSAT033)

HIV Infection

United Kingdom
Zimmer Biomet

Completed

MIS MiLIF Versus Open

Chronic Low Back Pain | Leg Pain

United States
ViiV Healthcare
Pfizer

Withdrawn

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Hepatitis B | Hepatitis C, Chronic | Human Immunodeficiency Virus

United States, Canada, Poland
French National Agency for Research on AIDS and...
Pfizer

Completed

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration (145 MARIMUNO)

HIV Infections | HIV Infection

France
French National Agency for Research on AIDS and...
Gilead Sciences; Hoffmann-La Roche

Completed

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

HIV Infections | Leukoencephalopathy, Progressive Multifocal

France
Abbott

Completed

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

Human Immunodeficiency Virus-Infection

Germany
St Stephens Aids Trust

Terminated

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

HIV Infections

United Kingdom
International Partnership for Microbicides, Inc.

Withdrawn

A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium

HIV Infections
ViiV Healthcare
Pfizer

Completed

Multicenter, Safety Study Of Maraviroc

Acquired Immunodeficiency Syndrome | HIV Infection

Brazil
Abbott

Completed

Evaluation of Kaletra Therapy Over the Long-term

Human Immunodeficiency Virus

Germany
ViiV Healthcare
Pfizer

No longer available

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

HIV

Canada
Hoffmann-La Roche
Trimeris

Terminated

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (AMICI)

HIV Infections

United States, Puerto Rico
ViiV Healthcare
Pfizer

Completed

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Healthy

Belgium
CIPRA SA
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities

HIV Infections
ViiV Healthcare
Pfizer; Copenhagen HIV Programme

Completed

EuroSIDA As An External Comparator To MOTIVATE Trials

HIV | AIDS
University of North Carolina, Chapel Hill

Completed

The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet

Pregnancy | HIV

United States
University of North Carolina, Chapel Hill
Pfizer

Completed

Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue

HIV/AIDS

United States
ViiV Healthcare
Pfizer

Completed

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

HIV Infections | Healthy

Singapore
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

United States, Belgium
GlaxoSmithKline

Terminated

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

HIV Infection

United States, Germany, Belgium, Canada, Denmark
University of California, San Francisco
Universitywide AIDS Research Program

Completed

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

HIV Infections

United States
ViiV Healthcare
Pfizer

Terminated

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Healthy

Singapore
Bristol-Myers Squibb

Completed

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

HIV Infections

United States
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

HIV Infections

Canada, United States, United Kingdom, Netherlands, Australia, Germany, Spain, Belgium, Switzerland
ViiV Healthcare
Pfizer

Completed

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Human Immunodeficiency Virus (HIV) Infection

Germany
Hospital Clinic of Barcelona

Unknown

Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 (DIS-MVC)

HIV-1 Infection

Spain
ViiV Healthcare
Pfizer

Completed

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

Human Immunodeficiency Virus (HIV) Infection

Singapore
ViiV Healthcare
Pfizer

Completed

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

HIV

United States, United Kingdom, Germany
ViiV Healthcare
Pfizer

Completed

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

HIV Infections

Netherlands, Germany, United Kingdom
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
St Stephens Aids Trust

Completed

Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

HIV Infections

United Kingdom
Massachusetts General Hospital
Bristol-Myers Squibb

Completed

Metabolic Effects of Switching Kaletra to Boosted Reyataz

HIV Infections

United States
Fundación Huésped
Pfizer

Unknown

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

AIDS | HIV-1 Adults Patients | Triple Class Failure

Argentina
University of Cologne

Completed

CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes

HIV Infections | Acquired Immunodeficiency Syndrome

Germany
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

Healthy Volunteers

Belgium
GlaxoSmithKline

Terminated

Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

Germany

3

Subscribe